Ferring Pharmaceuticals Opens New U.S. Operations Center With Plans For Significant Job Growth In New Jersey
December 5, 2014
By Mark Terry, BioSpace.com Breaking News Staff
Switzerland-based Ferring Pharmaceuticals opened its new U.S. Operations Center yesterday at 100 Interpace Parkway in Parsippany, N.J. The center will employ 275 people as managers, administrators, commercial operators, as well as manufacturing and research and development. The company invested $135 million in existing facilities.
“This is just the start of an exciting journey of growth to come,” said Michel Pettigrew, CEO of Ferring Holding Inc. and president of the executive board and COO of Ferring Group in a statement. “We hope this new operations center stands as a symbol of our philosophy as a company—a place where our commitment to the science and to our patients is front and center; a learning environment where employees are encouraged to take initiative and stretch beyond their designated role; and a cornerstone of the community, dedicated to giving back.”
Today the company also announced a new manufacturing facility being build in Ambernath, Mumbai, India. The facility, expected to open in 2015, is to be used to manufacture Ferring’s name brand product, Pentasa, a treatment for inflammatory bowel disease.
Ferring, with corporate headquarters in Saint-Prex, Switzerland, operates in approximately 60 countries and employs 5,000 people worldwide. It sells its drugs and compounds in 110 countries. In addition to the new facilities in the U.S. and India, it has production plants in South America, Israel, China, Denmark and several countries in Europe. The company’s focus is on reproductive health, urology, gastroenterology, endocrinology and orthopedics.
Of the U.S. facility, which will employ 275 people, the company expects to expand that number as its production goes live over the next 18 to 24 months.
“This grand opening serves as a reminder of our commitment to the U.S., New Jersey and to our long-term view on the science that cane make a real difference in the lives of the patients we serve,” said Aaron Graff, president and COO of Ferring Pharmaceuticals, in a statement. “As I watch our teams start to integrate into the new operations center, I already see the positive impact the space has on our ability to collaborate across functions within the organization and provide a premium workspace for our employees.”
Within the U.S., Ferring expects to develop, manufacture, package and deliver more than $200 million in products each year to the U.S. market. Although the company has received some state grants for the expansion, they did not apply for tax credits as incentives to remain in New Jersey.